Tag Archives: investing

Hot Investor Mandate: VC Firm With US and Asia Offices Invests in Early-Stage Life Science Companies in Seed to Series A Rounds

16 Dec

A venture capital firm with offices in US and Asia primarily invests in Seed and Series A rounds, although the firm is not stage-focused or valuation sensitive, as the core focus is on return opportunities. The firm has a global investment team covering healthcare, consumer, enterprise, frontier, fintech, and more. The firm invests globally and typically acts as a co-investor, making approximately 2–5 new portfolio investments per quarter and 2–5 follow-on investments per quarter. Initial check sizes can be up to $1M USD. 

As a generalist investor within healthcare, the firm seeks transformative technologies that shape the future of the sector. 

The firm values founders with a clear vision to solve fundamental problems at the root cause level, emphasizing cost-effective solutions that can benefit large populations. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Global Pharma With Investment Subsidiary Seeks Companies Developing Novel Drugs, Open to Various Modalities

16 Dec

The firm is a publicly listed pharmaceutical company with a global workforce and an international footprint that includes over 40 branches and subsidiaries worldwide. The firm’s core businesses are active pharmaceutical ingredients and generic drugs, while the firm is rapidly expanding into innovative drug development, including small molecules, biologics, and cell and gene therapies. A U.S.-based subsidiary operates as an integrated platform with research and development, manufacturing, and commercial capabilities, supplying generic drugs to major pharmacy chains, mass retailers, and grocery channels. 

Another subsidiary of the firm is responsible for equity investments and business development activities, including in-licensing and supplier or distributor partnerships, across both the China and U.S. markets. 

The firm is most interested in companies developing novel drugs across biologics, cell therapy, gene therapy, repurposed drugs, and biosimilars. From a development-stage perspective, the firm prefers programs at or before the NDA stage, including preclinical, Phase I, Phase II, Phase III, and NDA-ready assets. 

In addition to general equity investment and business development opportunities, the firm has particular interest in late-stage clinical assets that can be in-licensed and introduced into the China market, technologies that improve API manufacturing and production efficiency, and injectable drug products. The firm is also interested in distribution rights in China for both innovative and generic drugs, as well as distribution rights in the United States, primarily for generic drugs. 

From a company and management team perspective, the firm generally favors partners with strong scientific and technical capabilities, clear development and regulatory strategies, and high-quality data packages that support clinical and commercial potential. The firm typically values management teams that demonstrate execution capability, openness to strategic collaboration, and a willingness to engage in cross-border partnerships aligned with manufacturing, regulatory, and commercialization objectives. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Innovator’s Pitch Challenge Winners Announced at RESI London 2025 

9 Dec

Attendees voted with their RESI Cash alongside judges’ scores to determine this year’s winners.

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is pleased to announce the winners of the Innovator’s Pitch Challenge (IPC) at RESI London 2025. This year’s competition featured 26 participating companies, each showcasing early-stage technologies to a panel of experienced investors and an audience of global attendees. 

The IPC remains a cornerstone of every RESI conference, allowing founders to present to a coordinated group of investors who provide interactive questions and valuable feedback. Attendees cast votes using their RESI Cash, which was combined with judges’ assessments to select this year’s top companies. 

Congratulations to the RESI London 2025 IPC winners: 

These companies stood out among a highly competitive group of innovators spanning therapeutics, medical devices, diagnostics, and digital health. 

Congratulations, as well, to the companies from each session who received the highest judges scores:  

Looking ahead: Applications are now open for Life Science Nation’s next European conference, taking place in Portugal on March 23, 2026. Companies interested in pitching can apply here. 

Apply to Pitch at RESI Europe

Tags: , , , , , , , , , , , ,

You are Invited! Join Kansai Life Science Accelerator Program (KLSAP) Demo Day at RESI JPM 2026 

2 Dec

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Join us for a special showcase of Japan’s most promising early-stage life science innovators at the KLSAP 2025 Demo Day, presented by the Kobe Biomedical Innovation Cluster (KBIC). This dynamic session will feature three finalists from the Kansai Life Science Accelerator Program alongside eight KBIC startups and alumni. Companies will deliver focused pitches highlighting new advances in therapeutics, medical platforms, diagnostics, and digital health, followed by live Q&A with global investors.

Hosted during RESI JPM 2026, this session is an excellent opportunity for investors, BD teams, and innovation scouts looking to connect with high-potential Japanese technologies poised for global expansion.

📅 January 13, 12:00–2:00pm PST
📍 Golden Gate C3 Room, Marriott Marquis San Francisco

Agenda: 
12:00–12:03 Opening – KLSAP Overview

12:03–12:45 KLSAP 2025 Demo Day 
Featuring 3 Finalist Companies (7 minute pitch + 6 minute Q&A with investor panel) 

C-Biomex GeneMedicine ixgene

12:45–12:50 KLSAP 2025 Demo Day Closing – KBIC Introduction 

12:50–1:53 KBIC Startups and Alumni Speed Pitches 
Featuring 8 startups (5 minute pitch) 

aceRNA-Technologies Celaid CellFiber
CynosBio FerroptoCure linqmed
quadlytics

1:53–2:00 KBIC Session Closing 

RSVP to Attend

Tags: , , , , , , , , , , , ,

Hot Investor Mandate: VC Firm Invests up to $3M Across 4 Pillars of Medical Devices

2 Dec

A venture capital firm with offices in the U.S. and Europe, with a dual-fund structure, invests across several industries, with one of its focuses in healthtech and medtech. The firm’s sweet spot on early-stage companies, focused on Pre-seed to Series A, with potential follow-on investment in Series B. Typical check sizes range from $ 500K – $ 3M. Geographically, the firm is open to opportunities globally and does not have a preference for leading or co-investing in rounds. 

Within life science and healthcare, the firm is interested in Medical Devices through a 4-Pillar focus: (1) Early detection technologies, (2) Robotics, automation, precision medicine, and minimally invasive devices, (3) Digital health and applications, (4)  Brain–computer interface 

Traditional biotech therapeutics is generally not of interest. The firm is agnostic in terms of indications/disease areas. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: French VC Firm Seeks Companies Intersecting Deep-Tech and Life Sciences 

2 Dec

A French venture capital firm historically focused on deep-tech and hardware but is now broadening their scope to sectors such as the intersection between deep-tech and life sciences. Currently investing from their second fund of USD $75M, the firm participates in Pre-Seed and Seed rounds, typically allocating between USD $500K – $2.5M. The firm prefers to lead or co-lead and looks at companies in Europe and the U.S. 

In terms of life sciences, the firm is open to digital health deep-tech companies but are not interested in apps. The firm does not look at traditional therapeutics but will look at therapeutics with a data component or multi-asset and platform technologies. The firm is also open to diagnostics, non-invasive medical devices, surgical tools, and biomanufacturing. The firm looks at companies that are in their pre-clinical and development stages. The firm is disease-agnostic. 

The firm may take a board or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Longevity-Focused VC Firm Invests $500K – $1.5M in the U.S. and Europe 

2 Dec

A venture capital firm founded in 2024 and has USD $40M under management seeks to invest in Pre-Seed and Seed stage longevity biotech companies developing technologies that can significantly extend healthy human lifespan and are scalable for everyone. Initial check size ranges between USD $250K – $1.5M with the ability to lead or co-lead. The firm is open to global companies but prefers the US, UK, and EU. 

The firm is open to all technologies, except single assets, that address longevity. Areas of interest include breakthroughs in multiple areas including AI, synthetic biology, stem cell therapies, gene sequencing and editing, protein engineering, tissue engineering, and more. Every company they invest in must have the potential to extend healthy human lifespan by at least 10+ years. Companies of interest are typically still in pre-clinical stages. The firm seeks out companies with a strong ethical foundation and robust scientific backing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries
Newer Entries →